Opinion|Videos|September 9, 2024
Strategies for Prevention and Screening of CRM Conditions
Key Takeaways
- Integrating early intervention strategies for HF and T2D can prevent CKD, enhancing patient outcomes and reducing disease progression.
- Standardized protocols and education are crucial for improving early CKD screening across diverse healthcare settings.
Experts in cardiometabolic risk management explore strategies for the prevention and screening of cardiometabolic conditions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What does a successful CRM prevention or screening program look like in practice?
- Can early intervention in patients with HF or T2D prevent CKD or vice versa?
- How can early screening for CKD be improved and effectively implemented across different healthcare settings?
- What specific steps can healthcare providers take to incentivize early screening and intervention for CRM conditions?
- How can payers structure their reimbursement models to incentivize early detection and management of conditions like CKD, HF, and T2D?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA to Remove Black Box Warnings From HRT, Debate Ensues
2
High Fiber Linked to Fewer Bowel Symptoms in CRC Survivors
3
A Prescription for Improving Biomarker Testing for More Patients
4
Risk-Based Contracts May Not Cut Low-Value Care in Medicare Advantage
5
